No positive readout yet — Personalis substrate dormant, Personalis deal priced on pipeline potential, TEM demand flat.

How the INTerpath-001 readout validates the Personalis acquisition and reprices the Tempus AI deal thesis INTerpath-001 readout Merck & Moderna · Phase 3 Aug 19, 2026 — validates the individualized mRNA neoantigen pathway as a registrational- advancing modality Personalis single-patient sequencing + MRD substrate Moderna depends on this tumor-sequencing pipeline to call neoantigens and dose patients tumor WGS paired normal neoantigen calling mRNA dose + MRD monitor substrate dormant until readout Tempus AI to acquire Personalis · Jul 20, 2026 folds the sequencing/MRD substrate into its AI precision-medicine platform ~$1.5B all-stock · $16.25/sh Investors reprice the deal thesis upward positive readout lifts the long-run commercial outlook of the acquired asset DEMAND FOR TEM SHARES ↑ deal thesis repriced upward